FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileSilexion Therapeutics Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SLXNW
Silexion Therapeutics Ltd. Stock AnalysisComprehensive stock analysis for Silexion Therapeutics Ltd. (SLXNW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSLXNW
SLXNW
Silexion Therapeutics Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
SLXNW
  1. Home
  2. Stocks
  3. Silexion Therapeutics Ltd.

Silexion Therapeutics Ltd.

🇺🇸SLXNW•NASDAQ

Silexion Therapeutics Ltd.

🇺🇸SLXNW•NASDAQ
Market cap
$70.26K
Sentiment

Your view on SLXNW

Mkt Cap
$70.26K
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Silexion Therapeutics Ltd.

Industry
Biotechnology
Sector
Healthcare
CEO
Ilan Hadar
Headquarters
The Goldyne Savad Institute of Gene Therapy, Jerusalem, TA, IL
Industry
Biotechnology
Sector
Healthcare
CEO
Ilan Hadar
Headquarters
The Goldyne Savad Institute of Gene Therapy, Jerusalem, TA, IL
Description

Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths.

Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer.

Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Silexion Therapeutics Ltd. from FRC's valuation model, read against the market price. SLXNW last traded at $0.0043; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Silexion Therapeutics Ltd.. Starting points for Silexion Therapeutics Ltd.: EPS -$71.54, beta -0.27 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Silexion Therapeutics Ltd.. Silexion Therapeutics Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Silexion Therapeutics Ltd.. Trailing twelve-month EPS for Silexion Therapeutics Ltd. stands at -$71.54. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 16, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$170.40-$1,128.00-$441.60
Low estimate-$170.40-$1,128.00-$441.60
High estimate-$170.40-$1,128.00-$441.60
No. of analysts111
Year-ago EPS-$23.851-$2,150.401—
Growth———

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$0.00
Low estimate$0.00$0.00$0.00
High estimate$0.00$0.00$0.00
No. of analysts000
Year-ago revenue$0.00$0.00—
Growth———

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 16, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Silexion Therapeutics Ltd.. Silexion Therapeutics Ltd. has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold SLXNW20 companies
Compare SLXNW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ACONAclarion, Inc.Medical - Healthcare Information Services$4M
  • AKTXAkari Therapeutics, PlcBiotechnology$16M
  • DRMADermata Therapeutics, Inc.Biotechnology$3M
  • FOXOFOXO Technologies Inc.Medical - Care Facilities$8,997
  • PIIIP3 Health Partners Inc.Medical - Care Facilities$9M
  • PPBTPurple Biotech Ltd.Biotechnology$225,077
  • REVBRevelation Biosciences, Inc.Biotechnology$2M
  • SYRSSyros Pharmaceuticals, Inc.Biotechnology$21,464

More Biotechnology companies

  • BPMUFBasilea Pharmaceutica AGOTC$871M
  • BPTHBio-Path Holdings, Inc.OTC$554,529
  • BPTSYBiophytis S.A.OTC$189,402
  • BRAXFBraxia Scientific Corp.OTC$30,017
  • BRCTFBioArctic AB (publ)OTC$3.4B
  • BRIBFBrii Biosciences LimitedOTC$136M
  • BRNSBarinthus Biotherapeutics plcNASDAQ$30M
  • BRTXBioRestorative Therapies, Inc.NASDAQ$2M
  • BRVEBraveheart Bio, Inc.NASDAQ$1.4B
  • BSEMBioStem Technologies, Inc.OTC$20M
  • BSSPBaseline Productions, Inc.OTC$74,377
  • BTAIBioXcel Therapeutics, Inc.NASDAQ$2M
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Silexion Therapeutics Ltd., and how their positions are changing. At a $70,256 market value, institutional positions materially move Silexion Therapeutics Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Silexion Therapeutics Ltd. executives and directors. Shares of Silexion Therapeutics Ltd. have traded between $0.02 and $0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Silexion Therapeutics Ltd.. Coverage tracks Silexion Therapeutics Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Silexion Therapeutics Ltd.

SLXNW Analysis
Fair
Past1
Growth2
Health3
Profit1
Value5

News

Latest Market News